For General Information, page-2882

Hi @George1972,

So you likely expect a deal to be done before DMD P2b results next year, but not before LGMD goes into P2 (i.e. P1 completed or perhaps not needed since safety has already been tested on DMD P1) and after a partnership deal on DMD, and at a share price of approx. $1.25 to $1.50 assuming no more dilution before then. Interesting.

So an acquisition deal before Christmas is off the cards in this scenario (unfortunate for the ex-directors with 43 million options), which makes sense, based on where the share price is currently and what shareholders are likely to accept.